Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Relative Bioavailability of Empagliflozin (BI 10773) (Final Formulation) Compared to Empagliflozin (BI 10773 XX) (Trial Formulation 2) in Healthy Male and Female Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 10773 (Final Formulation)
Drug: BI 10773 XX (Trial Formulation 2)

First Posted Date: 2010-11-16

Last Posted Date: 2014-06-18

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 24

Registration Number: NCT01242176

Locations: 🇩🇪
1245.51.1 Boehringer Ingelheim Investigational Site, Biberach, Germany

Pharmacokinetics of Dabigatran Etexilate (Pradaxa®) During Haemodialysis

Phase 1

Completed

Conditions: Cardiovascular Diseases
Kidney Failure, Chronic

Interventions: Drug: Dabigatran etexilate

First Posted Date: 2010-11-16

Last Posted Date: 2014-04-07

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 7

Registration Number: NCT01241539

Locations: 🇩🇪
1160.121.1 Boehringer Ingelheim Investigational Site, Berlin, Germany

Randomised, Double- Blind, Cross-over Efficacy and Safety Comparison of Three Different Doses of Tiotropium Administered Once Daily Versus Placebo in Patients With Moderate Persistent Asthma.

Phase 2

Completed

Conditions: Asthma

Interventions: Drug: tiotropium bromide 1.25µg once daily
Drug: tiotropium bromide 2.5µg once daily
Drug: tiotropium bromide high dose once daily
Drug: Tiotropium matching Placebo once daily

First Posted Date: 2010-11-03

Last Posted Date: 2013-12-24

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 149

Registration Number: NCT01233284

Locations: 🇩🇪
205.380.49010 Boehringer Ingelheim Investigational Site, Berlin, Germany
🇺🇦
205.380.38003 Boehringer Ingelheim Investigational Site, Kharkiv, Ukraine
🇺🇦
205.380.38004 Boehringer Ingelheim Investigational Site, Kharkiv, Ukraine

and more 16 locations

PETRO Stroke Prevention in Patients With AF by Treatment With Dabigatran, With and Without Aspirin, Compared to Warfarin

Phase 2

Completed

Conditions: Atrial Fibrillation

Interventions: Drug: dabigatran with ASA
Drug: dabigatran without ASA
Drug: warfarin

First Posted Date: 2010-10-25

Last Posted Date: 2014-05-05

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 502

Registration Number: NCT01227629

Locations: 🇺🇸
1160.20.10015, Baltimore, Maryland, United States
🇩🇰
1160.20.45010, Aalborg, Denmark
🇩🇰
1160.20.45005 Aarhus Sygehus, Aarhus C, Denmark

and more 35 locations

BIBR 1048 Dose Range Finding Study in Prevention of Venous Thromboembolism in Patients With Primary Elective Total Hip or Knee Replacement Surgery

Phase 2

Completed

Conditions: Venous Thromboembolism

Interventions: Drug: BIBR 1048
Drug: Enoxaparin

First Posted Date: 2010-10-21

Last Posted Date: 2014-05-19

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 1973

Registration Number: NCT01225822

Locations: 🇦🇹
1160.19.43001 A.ö. Krankenhaus d. Statutarstadt Wiener Neustadt, Wr. Neustadt, Austria
🇨🇿
1160.19.42006 Hospital Mlada Boleslav, Mlada Boleslav, Czech Republic
🇧🇪
1160.19.32005 Virga Jesseziekenhuis, Gent, Belgium

and more 56 locations

Tiotropium Respimat Pharmacokinetic Study in COPD

Phase 2

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: Tiotropium low
Drug: Tiotropium medium
Drug: Tiotropium high
Drug: Tiotropium 18mcg
Drug: Tiotropium placebo

First Posted Date: 2010-10-18

Last Posted Date: 2014-05-16

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 154

Registration Number: NCT01222533

Locations: 🇧🇪
205.458.32002 Boehringer Ingelheim Investigational Site, Hasselt, Belgium
🇩🇪
205.458.49001 Boehringer Ingelheim Investigational Site, Hannover, Germany
🇧🇪
205.458.32003 Boehringer Ingelheim Investigational Site, Genk, Belgium

and more 8 locations

Telmisartan 80mg Non-responder Trial

Phase 3

Completed

Conditions: Hypertension

Interventions: Drug: Telmisartan
Drug: Telmisartan and amlodipine

First Posted Date: 2010-10-18

Last Posted Date: 2014-06-27

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 174

Registration Number: NCT01222520

Locations: 🇯🇵
1235.36.04 Boehringer Ingelheim Investigational Site, Hiroshima, Hiroshima, Japan
🇯🇵
1235.36.02 Boehringer Ingelheim Investigational Site, Shinjuku-ku, Tokyo, Japan
🇯🇵
1235.36.01 Boehringer Ingelheim Investigational Site, Chuo-ku,Tokyo, Japan

and more 1 locations

Relative Bioavailability of Two Different Batches of a Linagliptin / Metformin Combination Tablet in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Linagliptin/Metformin (standard batch)
Drug: Linagliptin/Metformin (side batch)

First Posted Date: 2010-10-07

Last Posted Date: 2014-06-27

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 40

Registration Number: NCT01216397

Locations: 🇩🇪
1288.6.1 Boehringer Ingelheim Investigational Site, Ingelheim, Germany

Pharmacokinetics, Safety and Tolerability of BI 671800 HEA Given Over 7 Days. A Randomised, Double Blind, Placebo Controlled Within Dose Groups Phase I Study in Healthy Male and Female Volunteers.

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 671800
Drug: Placebo

First Posted Date: 2010-10-07

Last Posted Date: 2013-11-01

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 24

Registration Number: NCT01215773

Locations: 🇩🇪
1268.59.1 Boehringer Ingelheim Investigational Site, Ingelheim, Germany

Single Rising Dose (SRD), Multiple Rising Dose (MRD) Study of BI 671800 in Healthy Asian Volunteers

Phase 1

Completed

Conditions: Asthma
Rhinitis, Allergic, Perennial

Interventions: Drug: BI 671800
Drug: placebo

First Posted Date: 2010-10-07

Last Posted Date: 2013-11-19

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 73

Registration Number: NCT01216384

Locations: 🇰🇷
1268.15.8201 Boehringer Ingelheim Investigational Site, Seoul, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy